Download: PDF RTF XML Booklet: Review (0) Retrieve Add item
HAI_FY2017 [HAI_FY2017] [748399] - Operating Grant
Activity 1. Organise conference at EU level on access to medicines by lead Stichting HAI

Start month:1 - End month: 11

(corresponds to Act. 1-3 FPA) Bringing together different HAI projects in 2015-16 work on access to medicines (research, workshops), organise a public conference at EU level on affordable access to ne...
(corresponds to Act. 1-3 FPA) Bringing together different HAI projects in 2015-16 work on access to medicines (research, workshops), organise a public conference at EU level on affordable access to needed medicines including transparency demands
Activity 2. Publications and meetings on TTIP by lead Stichting HAI

Start month:1 - End month: 12

Based on previous work (e.g. Act. 4 SGA 2015 and Act. 3 SGA 2016) publications on TTIP and access to medicines, provide technical expertise to policy makers and CSOs in TTIP negotiations
Activity 3. Involvement in TACD by lead Stichting HAI

Start month:1 - End month: 12

HAI acts as EU co-chair of TACD’s IP Committee by participating and 1) contributing to Steering Committee meetings (2) contributing to annual TACD public meeting and (3) co-drafting TACD resolutions...
HAI acts as EU co-chair of TACD’s IP Committee by participating and 1) contributing to Steering Committee meetings (2) contributing to annual TACD public meeting and (3) co-drafting TACD resolutions relevant to HAI’s work
Activity 4. Organise a conference in the Netherlands on transparency of R&D costs and medicines prices by lead Stichting HAI

Start month:1 - End month: 12

Act 4: (corresponds to Act. 1-3 FPA) Follow-up on 2016 social media campaign in Netherlands, organise public conference on policy mechanisms that enable transparency of medicines prices and (public sh...
Act 4: (corresponds to Act. 1-3 FPA) Follow-up on 2016 social media campaign in Netherlands, organise public conference on policy mechanisms that enable transparency of medicines prices and (public share) of R&D costs
Activity 5. Communication materials and meetings on AMR and new R&D models by lead Stichting HAI

Start month:1 - End month: 12

(corresponds to Act 4 FPA) Use 2016 AMR policy paper to raise awareness and enhance technical expertise about policy solutions that support uptake of new R&D models that respond to AMR and improve aff...
(corresponds to Act 4 FPA) Use 2016 AMR policy paper to raise awareness and enhance technical expertise about policy solutions that support uptake of new R&D models that respond to AMR and improve affordable access
Activity 6. Organise a workshop about education on pharmaceutical promotion in medical curriculum by lead Stichting HAI

Start month:1 - End month: 11

(corresponds to Act. 5 FPA): Organise workshop with experts to identify barriers preventing adequate teaching on pharmaceutical promotion in medical school curricula and CME, and issue recommendations...
(corresponds to Act. 5 FPA): Organise workshop with experts to identify barriers preventing adequate teaching on pharmaceutical promotion in medical school curricula and CME, and issue recommendations for this subject to be formalised in the curriculum
Activity 7. Briefing paper on pharmaceutical promotion of antibiotics by lead Stichting HAI

Start month:1 - End month: 11

Act. 7 (corresponds to Act. 7 FPA): Research the extent of the pharmaceutical industry’s promotion of antibiotics to patients and healthcare professionals and issue policy relations where needed to ...
Act. 7 (corresponds to Act. 7 FPA): Research the extent of the pharmaceutical industry’s promotion of antibiotics to patients and healthcare professionals and issue policy relations where needed to improve the rational use of antibiotics.
Activity 8. Communication materials and meetings on clinical trial data transparency and medicines marketing authorisation by lead Stichting HAI

Start month:1 - End month: 12

Act. 8 (corresponds to Act. 6 FPA): Advocate for greater transparency of clinical trial data and stronger requirements for marketing medicines authorisation (addressing concerns on early access scheme...
Act. 8 (corresponds to Act. 6 FPA): Advocate for greater transparency of clinical trial data and stronger requirements for marketing medicines authorisation (addressing concerns on early access schemes such as conditional marketing authorisation, adaptive pathways)
Activity 9. Develop communication materials on all HAI's areas of work by lead Stichting HAI

Start month:1 - End month: 12

Act. 9 (corresponds to Act 8, 9 FPA): Develop communications materials on all HAI’s areas of work: affordable access to medicines; rational use and democratisation of medicines policy
Activity 10. Provide technical expertise to relevant stakeholders by lead Stichting HAI

Start month:1 - End month: 12

Act. 10 (corresponds to Act 8 and 9 FPA): Provide technical expertise to relevant stakeholders (policymakers, regulators, CSOs) on all HAI’s areas of work
Activity 11. Strengthen HAI Europe's network by lead Stichting HAI

Start month:1 - End month: 12

(corresponds to Act. 10 FPA) Maintain and strengthen HAI Europe network’s engagement in EU medicines policy debates; organise Annual General Meeting and Board meetings
Activity 12. Contribute to financial sustainability of HAI Europe's network by lead Stichting HAI

Start month:1 - End month: 12

(corresponds to Act. 12 FPA): Contribute to financial sustainability of HAI Europe’s network